Option chain shows key data for Synaptogenix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Synaptogenix.

Synaptogenix (NASDAQ:SNPX) Stock, Option Chain

Synaptogenix

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

influencer-4081842

News

SNPX

Synaptogenix shares are trading lower Thursday morning. The company announced a 1-for-25 reverse stock split.

What&#39;s Going On With Synaptogenix (SNPX) Stock?

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACVA

AGRX

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ATNI

BBLG

BELFA

BZFD

DOCN

DPRO

EAST

ETSY

EZFL

GBNH

GSHD

INDV

KTOS

LCID

LNTH

LRHC

LUNG

MATV

MGPI

MNPR

MNTS

NOVA

NVAX

NVDA

OCUL

QTWO

RELY

RILY

RIVN

ROOT

RXRX

SMCI

SNPS

TRUE

VERO

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

BELFB

EFOI

ELAB

ALPS ETF Trusthen & Steers Global Realty Majors ETF

Shares of  NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.

Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Synaptogenix Inc

SNP SCHNEIDER NEUREITHER by SNP Schneider Neureither & Partner AG

Press Releases

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Offerings

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Aditxt

Alzamend Neuro

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Galecto

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

SILO Pharma

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Maxim Group

Comments

Synaptogenix

Synaptogenix (SNPX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell